MedPlus Subsidiary Faces Drug License Suspensions in Telangana and Andhra Pradesh

1 min read Updated on 29 Nov 2025, 05:36 PM

Reviewed by

Riya DScanX News Team

Overview

Medplus Health Services Limited announced that its subsidiary, Optival Health Solutions Private Limited, received suspension orders for drug licenses at two stores in Telangana and Andhra Pradesh. Each store faces a two-day suspension under the Drugs and Cosmetics Act. The company estimates a combined revenue loss of Rs 1.73 lacs due to these suspensions. Medplus has committed to providing detailed information on its website and stock exchange platforms.

*this image is generated using AI for illustrative purposes only.

Medplus Health Services Limited , a prominent player in the Indian pharmacy retail sector, has disclosed regulatory setbacks affecting its subsidiary, Optival Health Solutions Private Limited. The company announced that two of its stores, one in Telangana and another in Andhra Pradesh, have received suspension orders for their drug licenses.

Suspension Details

The suspension orders were issued for stores located in Telangana and Andhra Pradesh under the Drugs and Cosmetics Act. The duration of the suspension is two days for each store.

Financial Impact

Medplus has provided an estimate of the potential financial impact of these suspensions:

Aspect	Details
Duration of Suspension	2 days per store
Estimated Combined Revenue Loss	Rs 1.73 lacs

Regulatory Compliance

The company has promptly disclosed this information in compliance with regulatory requirements. This disclosure aligns with SEBI's recent circulars aimed at enhancing transparency in corporate communications.

Investor Information

Medplus has assured stakeholders that detailed information regarding these regulatory actions will be made available on the company's official website. Additionally, the information will be accessible on the websites of BSE Limited and National Stock Exchange of India Ltd.

While the immediate financial impact appears limited, these incidents underscore the importance of regulatory compliance in the pharmaceutical retail sector. Investors and stakeholders may want to monitor any potential long-term implications or recurring compliance issues that could affect the company's operations or reputation.

Historical Stock Returns for Medplus Health Services

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.09%	-0.04%	-2.98%	-1.73%	+17.86%	-26.41%

Medplus Health Services

View Company Insights

View All News

MedPlus Subsidiary Faces Drug License Suspension in Karnataka

1 min read Updated on 20 Nov 2025, 04:12 PM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

Overview

Optival Health Solutions, a subsidiary of Medplus Health Services, received suspension orders for drug licenses at two stores in Karnataka. The suspensions, issued by the Assistant Director of Drugs Control Administration in Hubli, will last for 3 days each at stores on R N Shetty Road and Vidyanagar Shirur Park. The potential revenue loss is estimated at Rs 3.49 lacs. The orders were issued under the Drugs and Cosmetics Act, 1940, and related Rules, 1945.

*this image is generated using AI for illustrative purposes only.

Medplus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has encountered regulatory challenges in Karnataka. The company recently received suspension orders for drug licenses at two of its stores in the state, as disclosed in a regulatory filing.

Suspension Details

The Assistant Director of Drugs Control Administration, Hubli Circle-Hubli, Karnataka, issued suspension orders for two Optival Health Solutions stores:

Store Location	Suspension Duration	Potential Revenue Loss
R N Shetty Road, Hubli	3 days	Rs 1.06 lacs
Vidyanagar Shirur Park	3 days	Rs 2.43 lacs

Regulatory Context

The suspensions were imposed under Rule 65 of the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The orders highlight the stringent regulatory environment in which pharmaceutical retail operations must function.

Financial Impact

While the immediate financial impact appears limited, with a combined potential revenue loss of approximately Rs 3.49 lacs for the affected stores, the incident underscores the importance of regulatory compliance in the pharmaceutical retail sector.

Company Response

Medplus Health Services Limited promptly disclosed this information to the stock exchanges, in compliance with SEBI regulations. The company's transparency in reporting such incidents is crucial for maintaining investor trust and adhering to corporate governance standards.

This development serves as a reminder of the regulatory risks faced by companies in the pharmaceutical retail space and the potential operational and financial consequences of non-compliance.

Historical Stock Returns for Medplus Health Services